MDMA’s Journey from Molly to Medicine

November 3, 2017

(Scientific American) – The speed and effectiveness of the psychedelic experience Casey describes has caught the attention of the Food and Drug Administration, despite the Drug Enforcement Administration’s 1985 classification of MDMA as a Schedule I substance—the murderer’s row of illicit drugs that include heroin and are deemed to have no medical value. This past August the FDA granted MDMA “breakthrough therapy” status in the treatment of PTSD, meaning it may provide a substantial improvement over existing therapies. The agency will work closely with MAPS—a privately funded research institute founded 31 years ago in Santa Cruz, California—to design and conduct phase III trials starting next spring. This marks the first time psychedelic-assisted psychotherapy will be monitored in phase III trials for possible prescription use.

Recommended Reading